- Home
- INAB vs GIGM Comparison
INAB vs GIGM Comparison
Compare INAB & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | GIGM |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 16.6M |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | INAB | GIGM |
|---|---|---|
| Price | $1.38 | $1.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 70.9K | 3.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.31 |
| 52 Week High | $4.20 | $1.89 |
Technical Indicators
Market Signals| Indicator | INAB | GIGM |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 39.99 |
| Support Level | $1.35 | N/A |
| Resistance Level | $2.14 | $1.58 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 33.33 | 27.27 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.